Tumoral and angiogenesis factors in hepatocellular carcinoma after locoregional therapy

Pathology Research and Practice

Volumn 208, Issue 1, 2012, Pages 15-21

  Farris, Alton B ^a   Dursun, Nevra ^a   Dhanasekaran, Renumathy ^b   Coban, Ipek ^a   McIntosh, Emily B ^a   Adsay, N Volkan ^a   Kim, Hyun S ^b  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b EMORY UNIVERSITY   (United States)

Author keywords

Hepatocellular carcinoma; Immunohistochemistry; Interventional radiology ablation; Ki 67; Necrosis; P53; VEGF

Indexed keywords

ANGIOGENIC FACTOR; CYTOKERATIN 19; CYTOKERATIN 7; KI 67 ANTIGEN; PROTEIN P53; VASCULOTROPIN;

ADULT; ARTICLE; CANCER GRADING; CANCER INVASION; CANCER STAGING; CELL PROLIFERATION; CHEMOEMBOLIZATION; CLINICAL ARTICLE; COMPARATIVE EFFECTIVENESS; CONTROLLED STUDY; DRUG ELUTING STENT; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LIVER CELL CARCINOMA; MALE; OUTCOME ASSESSMENT; TREATMENT OUTCOME; TUMOR VASCULARIZATION;

ADULT; AGED; ANTINEOPLASTIC AGENTS; CARCINOMA, HEPATOCELLULAR; CHEMOEMBOLIZATION, THERAPEUTIC; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KI-67 ANTIGEN; LIVER NEOPLASMS; MALE; MIDDLE AGED; NECROSIS; NEOPLASM STAGING; NEOVASCULARIZATION, PATHOLOGIC; TUMOR MARKERS, BIOLOGICAL; VASCULAR ENDOTHELIAL GROWTH FACTOR A; YOUNG ADULT;

EID: 84855805682     PISSN: 03440338     EISSN: 16180631     Source Type: Journal    
DOI: 10.1016/j.prp.2011.10.005     Document Type: Article

References (45)

1. Bartlett A., Heaton N. Hepatocellular carcinoma: defining the place of surgery in an era of organ shortage. World J. Gastroenterol. 2008, 14:4445-4453.
2. Belghiti J., Carr B.I., Greig P.D., Lencioni R., Poon R.T. Treatment before liver transplantation for HCC. Ann. Surg. Oncol. 2008, 15:993-1000.
3. Cucchetti A., Piscaglia F., Grigioni A.D., Ravaioli M., Cescon M., Zanello M., Grazi G.L., Golfieri R., Grigioni W.F., Pinna A.D. Preoperative prediction of hepatocellular carcinoma tumour grade and micro-vascular invasion by means of artificial neural network: a pilot study. J. Hepatol. 2010, 52:880-888.
4. Dhanasekaran R., Kooby D.A., Staley C.A., Kauh J.S., Khanna V., Kim H.S. Comparison of conventional transarterial chemoembolization (TACE) and chemoembolization with doxorubicin drug eluting beads (DEB) for unresectable hepatocelluar carcinoma (HCC). J. Surg. Oncol. 2010, 101:476-480.
5. Edmondson H.A., Steiner P.E. Primary carcinoma of the liver: a study of 100 cases among 48,900 necropsies. Cancer 1954, 7:462-503.
6. Ellis L.M., Hicklin D.J. VEGF-targeted therapy: mechanisms of anti-tumour activity. Nat. Rev. Cancer 2008, 8:579-591.
7. Farazi P.A., DePinho R.A. Hepatocellular carcinoma pathogenesis: from genes to environment. Nat. Rev. Cancer 2006, 6:674-687.
8. Fischer C., Mazzone M., Jonckx B., Carmeliet P. FLT1 and its ligands VEGFB and PlGF: drug targets for anti-angiogenic therapy?. Nat. Rev. Cancer 2008, 8:942-956.
9. Flaherty K.T., Sun W. Which questions remain unanswered following the successful development of sorafenib in hepatocellular carcinoma?. Nat. Clin. Pract. Oncol. 2009, 6:64-65.
10. Goodman Z.D. Neoplasms of the liver. Mod. Pathol. 2007, 20(Suppl. 1):S49-S60.
11. Ivy S.P., Wick J.Y., Kaufman B.M. An overview of small-molecule inhibitors of VEGFR signaling. Nat. Rev. Clin. Oncol. 2009, 6:569-579.
12. Jia J.B., Zhuang P.Y., Sun H.C., Zhang J.B., Zhang W., Zhu X.D., Xiong Y.Q., Xu H.X., Tang Z.Y. Protein expression profiling of vascular endothelial growth factor and its receptors identifies subclasses of hepatocellular carcinoma and predicts survival. J. Cancer Res. Clin. Oncol. 2009, 135:847-854.
13. Kamath P.S., Wiesner R.H., Malinchoc M., Kremers W., Therneau T.M., Kosberg C.L., D'Amico G., Dickson E.R., Kim W.R. A model to predict survival in patients with end-stage liver disease. Hepatology 2001, 33:464-470.
14. Kerbel R.S. Tumor angiogenesis. N. Engl. J. Med. 2008, 358:2039-2049.
15. Kooby D.A., Egnatashvili V., Srinivasan S., Chamsuddin A., Delman K.A., Kauh J., Staley C.A., Kim H.S. Comparison of yttrium-90 radioembolization and transcatheter arterial chemoembolization for the treatment of unresectable hepatocellular carcinoma. J. Vasc. Interv. Radiol. 2010, 21:224-230.
16. Kudo M. Multistep human hepatocarcinogenesis: correlation of imaging with pathology. J. Gastroenterol. 2009, 44(Suppl. 19):112-118.
17. Lauwers G.Y., Terris B., Balis U.J., Batts K.P., Regimbeau J.M., Chang Y., Graeme-Cook F., Yamabe H., Ikai I., Cleary K.R., Fujita S., Flejou J.F., Zukerberg L.R., Nagorney D.M., Belghiti J., Yamaoka Y., Vauthey J.N. Prognostic histologic indicators of curatively resected hepatocellular carcinomas: a multi-institutional analysis of 425 patients with definition of a histologic prognostic index. Am. J. Surg. Pathol. 2002, 26:25-34.
18. Lewandowski R.J., Kulik L.M., Riaz A., Senthilnathan S., Mulcahy M.F., Ryu R.K., Ibrahim S.M., Sato K.T., Baker T., Miller F.H., Omary R., Abecassis M., Salem R. A comparative analysis of transarterial downstaging for hepatocellular carcinoma: chemoembolization versus radioembolization. Am. J. Transplant. 2009, 9:1920-1928.
19. Li K.K., Neuberger J. The management of patients awaiting liver transplantation. Nat. Rev. Gastroenterol. Hepatol. 2009, 6:648-659.
20. Llovet J.M., Bruix J. Molecular targeted therapies in hepatocellular carcinoma. Hepatology 2008, 48:1312-1327.
21. Llovet J.M., Ricci S., Mazzaferro V., Hilgard P., Gane E., Blanc J.F., de Oliveira A.C., Santoro A., Raoul J.L., Forner A., Schwartz M., Porta C., Zeuzem S., Bolondi L., Greten T.F., Galle P.R., Seitz J.F., Borbath I., Haussinger D., Giannaris T., Shan M., Moscovici M., Voliotis D., Bruix J. Sorafenib in advanced hepatocellular carcinoma. N. Engl. J. Med. 2008, 359:378-390.
22. Luna L.E., Kwo P.Y., Roberts L.R., Mettler T.A., Gansen D.N., Andrews J.C., Wiseman G.A., Misra V.L. Liver transplantation after radioembolization in a patient with unresectable HCC. Nat. Rev. Gastroenterol. Hepatol. 2009, 6:679-683.
23. Marin H.L., Furth E.E., Olthoff K., Shaked A., Soulen M.C. Histopathologic outcome of neoadjuvant image-guided therapy of hepatocellular carcinoma. J. Gastrointestin Liver Dis. 2009, 18:169-176.
24. Mazzaferro V., Regalia E., Doci R., Andreola S., Pulvirenti A., Bozzetti F., Montalto F., Ammatuna M., Morabito A., Gennari L. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N. Engl. J. Med. 1996, 334:693-699.
25. Nalesnik M.A., Federle M., Buck D., Fontes P., Carr B.I. Hepatobiliary effects of 90yttrium microsphere therapy for unresectable hepatocellular carcinoma. Hum. Pathol. 2009, 40:125-134.
26. Nishihara Y., Aishima S., Kuroda Y., Iguchi T., Taguchi K., Asayama Y., Taketomi A., Kinukawa N., Honda H., Tsuneyoshi M. Biliary phenotype of hepatocellular carcinoma after preoperative transcatheter arterial chemoembolization. J. Gastroenterol. Hepatol. 2008, 23:1860-1868.
27. Pandey D., Lee K.H., Wai C.T., Wagholikar G., Tan K.C. Long term outcome and prognostic factors for large hepatocellular carcinoma (10cm or more) after surgical resection. Ann. Surg. Oncol. 2007, 14:2817-2823.
28. Parkin D.M., Bray F., Ferlay J., Pisani P. Global cancer statistics, 2002. CA Cancer J. Clin. 2005, 55:74-108.
29. Perry K.A, Enestvedt C.K., Hosack L.W., Pham T.H., Diggs B.S., Teh S., Orloff S., Winn S., Hunter J.G., Sheppard B.C. Increased vascular endothelial growth factor transcription in residual hepatocellular carcinoma after open versus laparoscopic hepatectomy in a small animal model. Surg. Endosc. 2010, 24:1151-1157.
30. Pugh R.N., Murray-Lyon I.M., Dawson J.L., Pietroni M.C., Williams R. Transection of the oesophagus for bleeding oesophageal varices. Br. J. Surg. 1973, 60:646-649.
31. Roberts L.R. Sorafenib in liver cancer-just the beginning. N. Engl. J. Med. 2008, 359:420-422.
32. Semela D., Dufour J.F. Angiogenesis and hepatocellular carcinoma. J. Hepatol. 2004, 41:864-880.
33. Spangenberg H.C., Thimme R., Blum H.E. Targeted therapy for hepatocellular carcinoma. Nat. Rev. Gastroenterol. Hepatol. 2009, 6:423-432.
34. Tanwar S., Khan S.A., Grover V.P., Gwilt C., Smith B., Brown A. Liver transplantation for hepatocellular carcinoma. World J. Gastroenterol. 2009, 15:5511-5516.
35. The Cancer of the Liver Italian Program (CLIP) investigators A new prognostic system for hepatocellular carcinoma: a retrospective study of 435 patients: the Cancer of the Liver Italian Program (CLIP) investigators. Hepatology 1998, 28:751-755.
36. The Cancer of the Liver Italian Program (CLIP) investigators Prospective validation of the CLIP score: a new prognostic system for patients with cirrhosis and hepatocellular carcinoma. The Cancer of the Liver Italian Program (CLIP) Investigators. Hepatology 2000, 31:840-845.
37. Villanueva A., Newell P., Chiang D.Y., Friedman S.L., Llovet J.M. Genomics and signaling pathways in hepatocellular carcinoma. Semin. Liver Dis. 2007, 27:55-76.
38. Wands J. Hepatocellular carcinoma and sex. N. Engl. J. Med. 2007, 357:1974-1976.
39. Wang B., Gao Z.Q., Yan X. Correlative study of angiogenesis and dynamic contrast-enhanced magnetic resonance imaging features of hepatocellular carcinoma. Acta Radiol. 2005, 46:353-358.
40. Wang C.C., Iyer S.G., Low J.K., Lin C.Y., Wang S.H., Lu S.N., Chen C.L. Perioperative factors affecting long-term outcomes of 473 consecutive patients undergoing hepatectomy for hepatocellular carcinoma. Ann. Surg. Oncol. 2009, 16:1832-1842.
41. Welker M.W., Zangos S., Kriener S., Monch C., Zeuzem S., Trojan J. Sequential therapy of transarterial chemoembolisation and sorafenib in intermediate stage hepatocellular carcinoma. J. Gastrointest. Cancer 2010, 41:149-152.
42. Yan B.C., Hart J.A. Recent developments in liver pathology. Arch. Pathol. Lab. Med. 2009, 133:1078-1086.
43. Yao F.Y. Liver transplantation for hepatocellular carcinoma: beyond the Milan criteria. Am. J. Transplant. 2008, 8:1982-1989.
44. Zavaglia C., De Carlis L., Alberti A.B., Minola E., Belli L.S., Slim A.O., Airoldi A., Giacomoni A., Rondinara G., Tinelli C., Forti D., Pinzello G. Predictors of long-term survival after liver transplantation for hepatocellular carcinoma. Am. J. Gastroenterol. 2005, 100:2708-2716.
45. Zhao Z.C., Zheng S.S., Wan Y.L., Jia C.K., Xie H.Y. The molecular mechanism underlying angiogenesis in hepatocellular carcinoma: the imbalance activation of signaling pathways. Hepatobiliary Pancreat. Dis. Int. 2003, 2:529-536.